Here is the design of a clinical trial:

Official Title: The Effect of Lifestyle and Risk Factor Modification on Occlusive Peripheral Arterial Disease Outcomes: Standard Healthcare vs Structured Programme

Included conditions:
- Peripheral Arterial Occlusive Disease

Study Armgroups:
- {'label': 'Risk Factors Modification Programme', 'type': 'EXPERIMENTAL', 'description': '* Patients in the intervention arm will attend a 12-week intensive lifestyle programme.\n* The intervention includes weekly exercise class and educational workshops, serial blood pressure, body mass index, glucose and lipid measurements.\n\n  * Weekly multidisciplinary team meetings and targeted and protocol pharmacotherapy to support lifestyle changes.', 'interventionNames': ['Behavioral: Risk Factors Modification Programme']}
- {'label': 'Standard Healthcare', 'type': 'ACTIVE_COMPARATOR', 'description': 'The control group will receive information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.', 'interventionNames': ['Behavioral: Standard Healthcare']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'Risk Factors Modification Programme', 'description': '12- week supervised risk factor modification programme derived from the Euroaction study standards', 'armGroupLabels': ['Risk Factors Modification Programme']}
- {'type': 'BEHAVIORAL', 'name': 'Standard Healthcare', 'description': 'Patients are advised to adjust lifestyle without the support of the structured supervised programme', 'armGroupLabels': ['Standard Healthcare']}

Primary Outcomes:
- {'measure': 'Lifestyle and medical risk factor modification', 'description': 'Achieving target Improvement in lifestyle risk factors. Target improvement will be considered if the patient achieves any one or more of the following:\n\n1. Smoking cessation\n2. Body mass index 20-25 (kg/m\\^2). BMI is calculated by dividing body weight in kilograms by the square of height in meters\n3. Glycosylated haemoglobin (HbA1c) less than 7%\n4. Total Cholesterol less than 5.0 mmol/L', 'timeFrame': 'at 12 weeks'}

Please estimate the sample size based on the assumption: 
Eighty percent statistical power and an alpha level of 5%
Sample size calculation
        For sample size calculation, the EUROACTION study [30] was used to estimate the coefficient of variation for sample proportions.
        Data from the EUROACTION [30] study suggest that 12-week intervention response rates for the primary endpoint of 54.8% (intervention programme) and 35.6% (usual care). Eighty percent statistical power and an alpha level of 5% were chosen. A two-sample comparison of proportions sample size calculation was implemented.
        With these parameters, the G*Power [31] software yields a trial with a maximum sample size of 208 patients completing the intervention (104 per intervention group).